Juan Carlos Hernández-Boluda, Diderik-Jan Eikema, Linda Koster, Nicolaus Kröger, Marie Robin, Moniek de Witte, Jürgen Finke, Maria Chiara Finazzi, Annoek Broers, Ludek Raida, Nicolaas Schaap, Patrizia Chiusolo, Mareike Verbeek, Carin L E Hazenberg, Kazimierz Halaburda, Aleksandr Kulagin, Hélène Labussière-Wallet, Tobias Gedde-Dahl, Werner Rabitsch, Kavita Raj, Joanna Drozd-Sokolowska, Giorgia Battipaglia, Nicola Polverelli, Tomasz Czerw, Ibrahim Yakoub-Agha, Donal P McLornan
Allogeneic hematopoietic cell transplantation (allo-HCT) is curative for myelofibrosis (MF) but assessing risk-benefit in individual patients is challenging. This complexity is amplified in CALR-mutated MF patients, as they live longer with conventional treatments compared to other molecular subtypes. We analyzed outcomes of 346 CALR-mutated MF patients who underwent allo-HCT in 123 EBMT centers between 2005 and 2019. After a median follow-up of 40 months, the estimated overall survival (OS) rates at 1, 3, and 5 years were 81%, 71%, and 63%, respectively...
September 7, 2023: Bone Marrow Transplantation